메타바이오메드

059210KOSDAQ의료용품 및 기타 의약 관련제품 제조업

70.8 / 100

Reference Date: 2026-07-24

Financial Score30.0 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Rose 10.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

MetaBioMed is a company specializing in the production and sale of medical devices and materials, including dental supplies, absorbable synthetic sutures, and cosmetic materials. The company focuses on dental nerve treatment materials and synthetic sutures, with growing demand for synthetic sutures replacing traditional animal-based products and sustained growth in the dental materials market.

Number of Employees

345people

Average Salary

52.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.98Industry Average 15.186.5Point

Lower than industry avg (good)

PBR

0.86Industry Average 1.094.0Point

In line with industry avg

ROE

9.75Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

1.68Industry Average 6.868.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲42.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 16.9% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
메타바이오메드, 주당 55원 중간배당 결정
메타바이오메드의 중간 배당 결정으로 주주 가치 증대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 3,935Won52-week high 6,52052-week low 3,530

1-month return5.0Point

1m +10.07% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 3Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral전환가액의조정2026-07-13
Positive자기주식취득결과보고서2026-07-03
Positive[기재정정]현금ㆍ현물배당결정2026-06-30
Neutral[기재정정]사업보고서 (2025.12)2026-06-29